BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18060334)

  • 21. Antiobesity drugs in early pregnancy and congenital malformations in the offspring.
    Källén BA
    Obes Res Clin Pract; 2014; 8(6):e571-6. PubMed ID: 25434912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
    Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Overweight patient has tried many times to lose weight. What helps against stubborn fat padding?].
    Wirth A
    MMW Fortschr Med; 2003 Mar; 145(10):16. PubMed ID: 12688021
    [No Abstract]   [Full Text] [Related]  

  • 26. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
    Caterson ID; Finer N
    Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity drug therapy.
    Baretić M
    Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.
    Anghelescu I; Klawe C; Szegedi A
    J Clin Psychopharmacol; 2002 Oct; 22(5):521-4. PubMed ID: 12352278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
    Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A drug help in reducing? Risk profile decides whether and how].
    Hauner H
    MMW Fortschr Med; 2003 May; 145(21):60. PubMed ID: 12845877
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for obesity.
    Neff LM; Aronne LJ
    Curr Atheroscler Rep; 2007 Dec; 9(6):454-62. PubMed ID: 18377785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of obesity.
    Finer N
    Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
    Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
    Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.